Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps

What Was Tested

This randomized controlled trial paper looks at Glucagon and Amylin (Islet Amyloid Polypeptide).

To assess the effects of adjunctive treatment with pramlintide, an analog of the beta-cell hormone amylin, on 24-h glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions in patients with type 1 diabetes intensively treated with continuous subcutaneous insulin infusion (CSII).

Who Took Part

The study group was 18 patients.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

At weeks 0 (baseline), 4 (on treatment), and 6 (2 weeks off treatment), 24-h interstitial glucose concentrations were measured using a continuous glucose monitoring system (CGMS), and postprandial plasma glucose, glucagon, and triglyceride concentrations were measured in response to a standardized test meal.

How the Study Was Run

In design terms this was a randomized study.

The patients were allocated by chance, so the Glucagon group and the comparison group should start out alike.

What Was Measured

Topics PubMed links to this paper include Amyloid, Blood Glucose, Diabetes Mellitus, Type 1, Fructosamine, Glucagon, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized study of Glucagon and Amylin (Islet Amyloid Polypeptide) in 18 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2003 (Diabetes care), a journal based in United States.

More context: the Glucagon compound page and the Amylin (Islet Amyloid Polypeptide) compound page, all human trials.